The estimated Net Worth of Vittal Vasista is at least $18.6 Milione dollars as of 19 March 2024. Mr. Vasista owns over 20,041 units of Regenxbio Inc stock worth over $3,133,447 and over the last 9 years he sold RGNX stock worth over $13,328,610. In addition, he makes $2,184,620 as Chief Financial Officer e Senior Vice President at Regenxbio Inc.
Sign up
Mr. Vasista RGNX stock SEC Form 4 insiders trading
Vittal has made over 48 trades of the Regenxbio Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 20,041 units of RGNX stock worth $75,354 on 19 March 2024.
The largest trade he's ever made was exercising 120,000 units of Regenxbio Inc stock on 7 February 2019 worth over $102,000. On average, Vittal trades about 12,463 units every 43 days since 2015. As of 19 March 2024 he still owns at least 246,534 units of Regenxbio Inc stock.
You can see the complete history of Mr. Vasista stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Vittal Vasista biography
Vittal K. Vasista serves as Chief Financial Officer, Senior Vice President of the Company. He has been our Chief Financial Officer since August 2009. Prior to joining us, Mr. Vasista served as Principal at PRTM Management Consultants from October 2006 to July 2009, where he developed operational strategies for both private and public organizations, including the development of market entry strategies, innovative business models, and operational improvements. Mr. Vasista received an M.B.A. from The Wharton School at the University of Pennsylvania, an M.S. in Mechanical Engineering from Stanford University, and an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology.
What is the salary of Vittal Vasista?
As the Chief Financial Officer e Senior Vice President of Regenxbio Inc, the total compensation of Vittal Vasista at Regenxbio Inc is $2,184,620. There are 2 executives at Regenxbio Inc getting paid more, with Kenneth Mills having the highest compensation of $6,147,270.
How old is Vittal Vasista?
Vittal Vasista is 52, he's been the Chief Financial Officer e Senior Vice President of Regenxbio Inc since 2019. There are 13 older and 6 younger executives at Regenxbio Inc. The oldest executive at Regenxbio Inc is Allan Fox, 72, who is the Chairman of the Board.
What's Vittal Vasista's mailing address?
Vittal's mailing address filed with the SEC is C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Insiders trading at Regenxbio Inc
Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas e Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.
What does Regenxbio Inc do?
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.
What does Regenxbio Inc's logo look like?
Complete history of Mr. Vasista stock trades at Regenxbio Inc
Regenxbio Inc executives and stock owners
Regenxbio Inc executives and other stock owners filed with the SEC include:
-
Kenneth Mills,
President, Chief Executive Officer, Executive Director -
Steve Pakola,
Senior Vice President, Chief Medical Officer -
Vittal Vasista,
Chief Financial Officer, Senior Vice President -
Olivier Danos,
Senior Vice President, Chief Scientific Officer -
Curran Simpson,
Senior Vice President - Product Development, Chief Technology Officer -
Kenneth T. Mills,
Pres, CEO & Director -
Vittal K. Vasista,
Chief Financial Officer -
Dr. Olivier Danos Ph.D.,
Chief Scientific Officer -
Curran M. Simpson M.S.,
Chief Operations & Technology Officer -
Patrick J. Christmas II, J.D.,
Chief Legal Officer -
Patrick J. Christmas II,
Chief Legal Officer -
Dr. Stephen Pakola,
Chief Medical Officer -
Luke Beshar,
Independent Director -
David Stump,
Independent Director -
Daniel Abdun-Nabi,
Independent Director -
A. N. Karabelas,
Lead Independent Director -
Daniel Tasse,
Independent Director -
Alexandra Glucksmann,
Independent Director -
Allan Fox,
Chairman of the Board -
Dr. Laura A. Coruzzi J.D., Ph.D.,
Sr. VP of Intellectual Property -
Ram Palanki,
Sr. VP of Commercial Strategy & Operations -
Dr. Laura A. Coruzzi,
Sr. VP of Intellectual Property -
Shiva G. Fritsch,
Chief People Officer -
Andrew Yost,
VP of Corp. Devel. -
Tricia Truehart,
VP of Investor Relations & Corp. Communications -
Stephen Yoo,
Chief Medical Officer -
Llc Fmr,
10% owner -
Camille D Samuels,
Director -
Faraz Ali,
Chief Business Officer -
Edgar Engleman,
Director -
James E Deerfield Mgmt L.P....,
-
Donald J Jr Hayden,
-
Patrick J. Christmas,
Chief Legal Officer -
Jean Bennett,
-
George V Migausky,
-
Jennifer Zachary,